Jaktinib

Phase 3Small molecule

SSuzhou Zelgen Biopharmaceuticals Co.,Ltd

Jaktinib is one of 243 small molecule programs targeting Pneumonia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

242

Competitors

Pipeline

Status by Indication[3][1]

Indication

PneumoniaActive, not recruiting

MyelofibrosisActive, not recruiting

PsoriasisActive, not recruiting

Atopic DermatitisActive, not recruiting

Alopecia AreataActive, not recruiting

Idiopathic Pulmonary FibrosisActive, not recruiting

Ankylosing SpondylitisActive, not recruiting

PneumoniaPhase 2

Active, not recruiting

MyelofibrosisPhase 2

Active, not recruiting

PsoriasisPhase 2

Active, not recruiting

Atopic DermatitisPhase 3

Active, not recruiting

Alopecia AreataPhase 3

Active, not recruiting

Idiopathic Pulmonary FibrosisPhase 2

Active, not recruiting

Ankylosing SpondylitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

605 competitors in Psoriasis

#DrugCompanyPhaseTrials

Jaktinib

SSuzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 3

1 2

Cosentyx

Novartis

Preclinical

53 3

Stelara

Johnson & Johnson

Preclinical

37 4

Taltz

Eli Lilly

Preclinical

20 5

Bimzelx

UCB

Preclinical

17 6

Humira

CCelltrion

Preclinical

42 7

Ilumya

Sun Pharmaceutical Industries, Inc.

Preclinical

15 8

Raptiva

Roche

Preclinical

10 9

Remicade

OOrganon and Co

Preclinical

20 10

Siliq

BBausch Health Americas, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Active, not recruiting

Atopic Dermatitis

NCT05526222

Clinical

Trials by Indication[1]

Pneumonia4 trials

An Efficacy and Safety Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia

Unknown status·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 2·NCT05686629·120 enrolled

A Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia

Unknown status·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 2·NCT05688839·60 enrolled

Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19)

Withdrawn·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 2·NCT05702788

Show 1 more trial

Efficacy and Safety of Jaktinib in Patients With COVID-19 Pneumonia.

Unknown status·FFirst Affiliated Hospital of Zhejiang University·Phase 2·NCT05672888·60 enrolled

Alopecia Areata4 trials

A Study With Jaktinib Hydrochloride Cream Applied Topically to Subjects With Alopecia Areata

Active, not recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 1/2·NCT04445363·160 enrolled

Study to Evaluate the Safety and Efficacy ofJaktinib Hydrochloride Tablets in Severe Alopecia Areata

Completed·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 2·NCT04034134·111 enrolled

Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata

Completed·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 3·NCT05051761·425 enrolled

Show 1 more trial

Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata

Completed·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 3·NCT05255237·315 enrolled

Myelofibrosis4 trials

Study of Jaktinib In Patients With Myelofibrosis Who Were Relapsed or Refractory of Ruxolitinib Treatment.

Completed·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 2·NCT04851535·34 enrolled

Jaktinib Hydrochloride Tablets in Intermediate-risk and High-risk Myelofibrosis.

Completed·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 2·NCT03886415·118 enrolled

Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis

Completed·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 2·NCT04217993·51 enrolled

Show 1 more trial

Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis

Completed·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 3·NCT04617028·105 enrolled

Atopic Dermatitis4 trials

A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic Dermatitis

Active, not recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 3·NCT05526222·443 enrolled

A Phase III Extended Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic Dermatitis

Recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 3·NCT05676242·400 enrolled

Jaktinib Hydrochloride Cream For Atopic Dermatitis

Completed·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 1/2·NCT04435392·107 enrolled

Show 1 more trial

Clinical Study of Jaktinib in the Treatment of Patients With Moderate and Severe Atopic Dermatitis

Completed·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 2·NCT04539639·166 enrolled

Ankylosing Spondylitis3 trials

Jaktinib Hydrochloride Tablets In The Treatment of Active Ankylosing Spondylitis

Completed·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 2·NCT04507659·108 enrolled

Extension Study to Evaluate Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS)

Unknown status·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 3·NCT05861128·258 enrolled

Efficacy and Safety Study of Jaktinib in Subjects With Active Ankylosing Spondylitis(AS)

Active, not recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 3·NCT05861102·265 enrolled

10 more indications

Hepatic Impairment1 trial

Pharmacokinetics Of Jaktinib In Subjects With Hepatic Impairment And Normal Hepatic Function

Completed·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 1·NCT04993404·24 enrolled

Fasting Conditions1 trial

Comparative Study on Pharmacokinetics of Two Formulations of Jaktinib in Healthy Adults Under Fasting Conditions

Completed·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 1·NCT06132243·52 enrolled

Tolerance1 trial

The Tolerance, Pharmacokinetics of Jaktinib in Healthy Volunteers

Completed·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 1·NCT03314402·126 enrolled

Idiopathic Pulmonary Fibrosis1 trial

Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis

Completed·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 2·NCT04312594·91 enrolled

Tics1 trial

A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Jaktinib in Healthy Volunteers

Completed·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 1·NCT06246695·40 enrolled

Steroid-Refractory Acute Graft-Versus-Host Disease1 trial

A Study of Jaktinib for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease.

Not yet recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 2·NCT04971551·60 enrolled

ART1 trial

A Study to Evaluate the Effect of Jaktinib on QT/QTc Interval in Healthy Participants

Completed·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 1·NCT06193148·32 enrolled

Psoriasis1 trial

A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis

Completed·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 2·NCT04612699·123 enrolled

MDS/MPN1 trial

Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.

Terminated·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 1/2·NCT04866056·1 enrolled

Unspecified1 trial

A Safety and Tolerability Study of Jaktinib

Recruiting·SSuzhou Zelgen Biopharmaceuticals Co.,Ltd·Phase 1·NCT05279001·26 enrolled

Sources

References

[1]
ClinicalTrials.gov — 29 trial records for Jaktinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Jaktinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Jaktinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Suzhou Zelgen Biopharmaceuticals Co.,Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSuzhou Zelgen Biopharmaceuticals Co.,Ltd

Jaktinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Pneumonia4 trials

Alopecia Areata4 trials

Myelofibrosis4 trials

Atopic Dermatitis4 trials

Ankylosing Spondylitis3 trials

Hepatic Impairment1 trial

Fasting Conditions1 trial

Tolerance1 trial

Idiopathic Pulmonary Fibrosis1 trial

Tics1 trial

Steroid-Refractory Acute Graft-Versus-Host Disease1 trial

ART1 trial

Psoriasis1 trial

MDS/MPN1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News